Related Experiment Video
Updated: Jun 21, 2025
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.1K
PCSK9 inhibition: from effectiveness to cost-effectiveness.
Iveta Mercep1,2, Dominik Strikic2, Pero Hrabac3
1Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia.
Frontiers in Cardiovascular Medicine
|July 11, 2024
Summary
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors effectively lower low-density lipoprotein (LDL) cholesterol for high-risk patients with dyslipidaemia. Their significant benefits are clear, though cost-effectiveness remains debated.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Dyslipidaemia, characterized by abnormal blood lipid levels, is a major modifiable risk factor for atherosclerotic cardiovascular disease.
- It arises from genetic and environmental factors, categorized as primary (inherited) or secondary (disease/medication-induced).
Purpose of the Study:
- To review the evolving treatment landscape for dyslipidaemia.
- To evaluate the efficacy, safety, and cost-effectiveness of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Main Methods:
- Systematic review of meta-analyses confirming PCSK9 inhibitor efficacy and safety.
- Analysis of cost-effectiveness studies and real-world patient data.
Main Results:
- PCSK9 inhibitors significantly reduce low-density lipoprotein (LDL) cholesterol levels.
- Clinical trials and initial patient data support their effectiveness, but long-term side effects and interactions are uncertain.
- Cost-effectiveness analyses yield mixed results, with varying conclusions across different healthcare systems.
Conclusions:
- PCSK9 inhibitors offer a revolutionary approach to lowering LDL cholesterol in dyslipidaemia.
- Despite cost controversies, their clear benefits for high-risk patients warrant consideration in treatment strategies.
More Related Videos
Related Concept Videos
01:22Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
01:14Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
119
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
119
01:16Bioequivalence: Overview
975
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
975
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
57
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
57